<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002030</url>
  </required_header>
  <id_info>
    <org_study_id>022E</org_study_id>
    <secondary_id>87-72B</secondary_id>
    <secondary_id>88-21</secondary_id>
    <nct_id>NCT00002030</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</brief_title>
  <official_title>An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fisons</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To evaluate the safety, tolerability, and efficacy of long term, bi-weekly administration of
      aerosol pentamidine when used as a prophylactic agent in patients who have had at least two
      or more episodes of AIDS-associated Pneumocystis carinii pneumonia (PCP).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Pneumonia, Pneumocystis Carinii</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentamidine isethionate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Zidovudine (AZT).

          -  Standard or experimental treatments for an opportunistic infection or neoplasm
             (including aerosolized or intravenous pentamidine) that develops during the study.

        Concurrent Treatment:

        Allowed:

          -  Any standard or experimental treatment for an opportunistic infection or neoplasm that
             develops during the study.

        Patients must have AIDS with at least one cytologically or histologically proven episode of
        Pneumocystis carinii pneumonia (PCP).

          -  Patients must be free of acute medical problems.

        Prior Medication:

        Allowed:

          -  Zidovudine (AZT).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Requiring ongoing active therapy for an opportunistic infection at the time of study
             entry.

          -  Toxoplasmosis.

          -  Cryptococcus.

          -  Pulmonary Kaposi's sarcoma (KS).

          -  Asthma poorly controlled by medication.

        Concurrent Medication:

        Excluded:

          -  Pentamidine by any route other than aerosolized or intravenous or any other
             experimental agent for chemoprophylaxis of PCP while on the study (e.g.:

          -  Septra, Fansidar, Dapsone, or eflornithine).

        Concurrent Treatment:

        Excluded:

          -  Transfusion dependency defined as &gt; 1 blood transfusion per month.

        Patients with the following are excluded:

          -  Requiring ongoing active therapy for an opportunistic infection (O.I.) at the time of
             entry or having either Toxoplasmosis or cryptococcosis at entry.

          -  Pulmonary Kaposi's sarcoma (KS).

          -  Active substance abuse by patients who cannot comply with study procedures.

          -  Unwilling to sign informed consent.

          -  In the opinion of the investigator cannot cooperate with study procedure.

          -  Asthma poorly controlled by medication.

          -  Patients may not receive pentamidine by any other route than aerosolized or
             intravenous or any other experimental agent for chemoprophylaxis of PCP while on the
             study (e.g.:

          -  Septra, Fansidar, Dapsone, or eflornithine).

        Prior Medication:

        Excluded within 30 days of study entry:

          -  Antiretroviral agents, excluding zidovudine (AZT).

          -  Immunomodulating agents.

          -  Corticosteroids.

        Prior Treatment:

        Excluded within 7 days of study entry:

          -  Blood transfusion.

          -  Excluded:

          -  Requiring ongoing active treatments for an opportunistic infection at time of study
             entry.

        Active substance abuse by patients who cannot comply with study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fisons Corp</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1989</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Pneumonia, Pneumocystis carinii</keyword>
  <keyword>Pentamidine</keyword>
  <keyword>Aerosols</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

